H. Seeger et al., Effect of oral contraceptives on the urinary excretion of biochemical markers indicating vasoactive action, J CLIN PH T, 25(3), 2000, pp. 221-226
Objective: In the present study the effect of two contraceptive pills, i.e.
Neorlest, containing ethinylestradiol and norethisterone acetate, and Vale
tte, containing ethinylestradiol and the new progestin dienogest, was inves
tigated on the urinary excretion of vasoactive markers. As markers prostacy
clin and its antagonist thromboxane, cGMP, serotonin, and the vasorelaxing
mediators relaxin and urodilatin were measured.
Method: 30 women received Neorlest and 33 women Valette in a randomized, op
en, parallel-group study design. Nocturnal urine was collected before treat
ment and during cyclic treatment after 6 and 11 weeks.
Results: For prostacyclin, the ratio of prostacyclin to thromboxane, relaxi
n and urodilatin significant increases compared to the pretreatment values
were observed with Valette within 11 weeks treatment. For the markers cGMP
and serotonin both contraceptive pills showed a tendency to an increase of
the renal excretion after 11 weeks treatment. No significant differences be
tween the two pills were observed, except in the case of the ratio of prost
acyclin to thromboxane, which showed a significant, clear-cut enhancement w
ith Valette.
Conclusion: These results indicate that contraceptive pills may stimulate t
he production of vasodilative markers, an effect which can be attributed mo
st likely to the oestrogenic component of the pill. The progestogenic compo
nent of the pill may elicit an impact on this oestrogen-induced vasodilatio
n, which, however, seems to be minimized in the case of the new compound di
enogest, a C-19 progestin with antiandrogenic properties.